Comparison of a Chromogenic Factor X Assay to International Normalized Ratio for Monitoring Oral Anticoagulation Therapy David L. McGlasson; Major Benjamin.

Slides:



Advertisements
Similar presentations
INR Purpose Monitor the coagulation of blood for those on anti-coagulation therapy Monitor for therapeutic levels of medication Monitor for.
Advertisements

A Multi-Laboratory Evaluation of a Chromogenic Factor X Assay for Monitoring Oral Anticoagulation Therapy DL McGlasson 1*; PN Shaklee 2; 1 59 th Clinical.
ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,
Anti-Phospholipid Antibody Syndrome The Annexin A5 Competition Assay as a Diagnostic Tool.
Unique Anticoagulation Issues at University Hospitals Case Medical Center Teresa L. Carman, MD Director, Vascular Medicine Case Medical Center Pager
Departments of Medicine and Biostatistics
General Approach of Haemostasis
General Approach of Haemostasis Prothrombin Time (Continue) Lecture 5:
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
One Stage Factor V Assay
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
MLAB Coagulation Keri Brophy-Martinez
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Printed by Prevalence of Heparin in Samples Submitted for Lupus Anticoagulant Testing Nikhil A. Sangle MD FRCPath 1,3, George M.
Implementation of local guideline by interactive workshop improves anticoagulation therapy and patient safety Puhakka J, Helsinki Health Centre, GP Suvanto.
©2007 Wortham Laboratories, Inc.
MIXING STUDIES General Approach of Haemostasis
Neurology APTT, PTT, PT, INR. Neurology APTT, PTT, PT, INR.
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
  The prothrombin time is therefore the time required for the plasma to clot after an excess of thromboplastin and an optimal concentration of calcium.
Effects of Pre-analytical Variables on the anti-Xa Chromogenic Assay when Monitoring Unfractionated Heparin and Low Molecular Weight Heparin Anticoagulation.
DiaPharma Factor X Chromogenic Factor X kit for monitoring oral anticoagulation therapy in patients with falsely elevated INRs.
History of the Prothrombin Time and Development of the INR Leon Poller European Concerted Action on Anticoagulation.
Analysis of Variance 1 Dr. Mohammed Alahmed Ph.D. in BioStatistics (011)
A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.
ITEC6310 Research Methods in Information Technology Instructor: Prof. Z. Yang Course Website: c6310.htm Office:
David Adler Research Interests Pharmaceutics Solubility - Phenytoin in IV Solutions Bioavailability/Clinical Equivalence - Sodium Warfarin - RCT Clinical.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Wins/Losses and Errors/Ties: Quality of Care for Acute Myocardial Infarction in the VA Health Care System Laura A. Petersen, M.D., M.P.H. 1 Sharon-Lise.
Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy R. Rossini, G. Musumeci,
A Multi-Laboratory Evaluation of a Chromogenic Factor X Assay for Monitoring Oral Anticoagulation Therapy DL McGlasson 1*; PN Shaklee 2; 1 59 th Clinical.
Praxbind® - Idarucizumab
Assessing Responsiveness of Health Measurements Ian McDowell, INTA, Santiago, March 20, 2001.
Laboratory Testing in Coagulation Coagulation Keri Brophy-Martinez.
Statistics Josée L. Jarry, Ph.D., C.Psych. Introduction to Psychology Department of Psychology University of Toronto June 9, 2003.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
A Screening Test for Xa based DOACs Uzma Ahmad BMS Haematology at The Mid Yorkshire Hospitals NHS Trust Introduction A study was undertaken to investigatie.
Comparison of Patient Satisfaction and Time Spent in Therapeutic Range in Two Different Clinic Models Ashley Pokallus, PharmD PGY1 Pharmacy Resident—Ambulatory.
Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis R2 이 홍 주 Am J Gastroenterol 2009 ; 104 : 673 ~ 678.
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
The NEW ENGLAND JOURNAL of MEDICINE Idarucizumab for Dabigatran Reversal R3 김동연 / F. 김선혜.
Date of download: 9/18/2016 From: Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants Ann Intern Med. 1997;127(3): doi: /
Introduction to Quality Assurance. Quality assurance vs. Quality control.
The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review Karim Bouferrache Pacific University.
Nguyen Ngoc Tu1,2, Marie-Christine Morel-Kopp3, Chris Ward 3, Robert G
General Approach of Haemostasis
Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,
Effects of rivaroxaban and apixaban on routine coagulation screening tests Sean Platton1*, Louise Bowles1, Peter MacCallum2 The Royal London Hospital,
Audit on the performance of Lupus Anticoagulant tests
Coagulation Function In Frail and Non-frail Older Inpatients With Atrial Fibrillation Tu N Nguyen1,2, Dominic Pepperell3, Marie-Christine Morel-Kopp3,
Evaluation of APTT clot waveform analysis by IL ACL TOP® in patients with Haemophilia and comparison to clot waveform analysis with MDA® 180 P-TH-568 Aghighi.
Evaluation of Protein C in Pregnant Nigerian Women
Shortened Coagulation profile in Pregnancy - A Comparative analysis in different trimesters: Retrospective study from a tertiary care centre Bhavika Rishi,
by Kueiyu Joshua Lin, Daniel E. Singer, Robert J
ASPIRE Workshop 5: Application of Biostatistics
ASPIRE Workshop 5: Application of Biostatistics
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
Nat. Rev. Nephrol. doi: /nrneph
Direct Oral Anticoagulants
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
General Approach in Investigation of Hemostasis
Coagulation Factor Assays
Heiko Lehrmann et al. JACEP 2018;j.jacep
ASPIRE Workshop 5: Application of Biostatistics
Effect of VKORC1 Haplotype Combination on Clinical Warfarin Dose - Common haplotypes (H1, H2, H7, H8, and H9) were clustered with use of the UPGMA method.
ZIKV ELISA results by NHP type and prior exposure.
Presentation transcript:

Comparison of a Chromogenic Factor X Assay to International Normalized Ratio for Monitoring Oral Anticoagulation Therapy David L. McGlasson; Major Benjamin G. Romick †, †, Bernard J. Rubal ‡ † Wilford Hall US Air Force Medical Center, Lackland Air Force Base, TX ‡ Brooke Army Medical Center, Fort Sam Houston, TX

Background The International Normalized Ratio (INR) is the primary method for monitoring patients on oral anticoagulation therapy (OAT). Numerous confounding variables limit monitoring of INR in patients on OAT –Lupus Anticoagulant (LA) –Converting direct thrombin inhibitors to OAT

Background Chromogenic Assay for Factor X (CFX) has been validated for use in monitoring patients with LA who are on OAT CFX is not affected by presence of LA and other variables that affect INR

Introduction CFX has not been compared to INR in monitoring a broad population of patients on OAT No universally defined range of values of CFX for: –Therapeutic anticoagulation –Supratherapeutic anticoagulation –Subtherapeutic anticoagulation

Introduction Study (n)INRCFX Rosborough % Moll % Moll, et al % Sanfellipo % Robert, et al %

Introduction Objectives of the present study: 1.Define the therapeutic range for CFX in this population 2.Assess the relationship between CFX and INR values in an outpatient “Coumadin Clinic” setting

Methods INR and CFX levels were evaluated in randomly selected excess specimens from the coumadin clinic and normal subjects not receiving anticoagulant therapy INR values were correlated to CFX for determining the following ranges for OAT patients: –Normal or SubtherapeuticINR < 2.0 –TherapeuticINR –SupratherapeuticINR > 3.0

Methods Instrumentation: –STA-R Evolution automated coagulation analyzer (Diagnostica-Stago, Inc.®, Parsippany, NJ) –Chromogenic Factor X assay (Diapharma, Inc.®, Westchester, OH) –INR performed with PT method using Neoplastine Cl+ with ISI of 1.28 and geometric mean of 13.8 seconds

Data Analysis Overall correlation of INR to CFX assessed with inverse square method (Sigmaplot version 9.01; Systat Software, Inc, San Jose, Ca) –Goodness of fit expressed as the coefficient of determination: R 2 Receiver Operator Characteristic (ROC) curves used to discriminate therapeutic ranges (SPSS version 11.5, SPSS, Inc. Chicago, IL) –ROC area > → highly discriminative –ROC area > → good discrimination

Data Analysis CFX ranges consistent with INR therapeutic ranges defined by plots of sensitivity and specificity versus CFX Kolmogorov-Smirnov test employed to assess normality of CFX distributions among therapeutic subsets Non-normally distributed data presented as median and 25 th and 75 th percentiles

Data Analysis One-way Analysis of Variance on Ranks (Sigmastat version 3.11; Systat Software, Inc., San Jose, CA) used to assess differences in CFX among INR therapeutic ranges Differences between groups assess used Dunn’s post hoc test P values < 0.05 are considered significant

Results 309 randomly selected OAT patients were tested 30 normal subjects not on anticoagulants tested for comparison Range of INR & CFX in OAT patients: –INR0.92 – –CFX9 – 132%

Results INR CFX Range (Mean) N < % (53%) – – 48% (28%) 135 > – 46% (21%) 104 Normals 72 – 131% 96% 30

Figure 1. Good model fit between INR and CFX when expressed as a second order inverse function (N = 339, r 2 = 0.929; P<0.001). Open circles represent samples from normal control group (CFXn), closed circles represent patients receiving Coumadin therapy (CFXc).

Figure 2A. ROC curve using INR ≥ 2.0 as criteria for the threshold of therapeutic anticoagulation. Figure 2B (arrow) is a plot of sensitivity and specificity over the range of CFX values tested (N = 339). The arrow indicates the CFX value ≤ 35.5% that has maximum combined sensitivity and specificity for the INR therapeutic threshold (INR ≥ 2.0).

Figure 3A is a ROC curve for the patients with INR ≥ 2.0 (N = 240) using an INR value >3.0 for discriminating therapeutic form surpratherapeutic ranges of CFX. Figure 3B is a plot of sensitivity and specificity vs CFX values. Arrow indicates that CFX ≤ 23.5% is consistent with an INR >3.0.

Figure 4 depicts box plots (median: solid line, mean: dotted line, whiskers: 10th and 90 th percentile) for CFX values categorized by INR therapeutic ranges. Significant differences were noted between all groups. Dashed lines indicate the CFX range (23.5%-35.5%) is equivalent to the INR therapeutic range (INR ).

Conclusion CFX correlates well with INR in a randomly selected group of OAT patients at varying levels of anticoagulation –R = by inverse square function CFX is highly discriminative for patients in therapeutic and subtherapeutic INR ranges –ROC curve area 0.948, p < , n = 339 CFX has good discrimination for patients in therapeutic and supratherapeutic INR range –ROC curve area 0.864, p < , n = 240

Conclusion CFX 2.0 –Sensitivity 91.7% –Specificity 91.9% CFX 3.0 –Sensitivity 78.2% –Specificity 84.6%

Conclusion Current findings suggest usefulness of CFX for monitoring oral anticoagulation in broad groups of patients seen in a coumadin clinic

Conclusion Further study warranted to compare outcomes in OAT patients monitored with CFX and conventional INR methods –Bleeding events –Thromboembolism –Cost –Convenience –Availability

References 1. Delate T, Witt DM, Jones JR, Bhardwaja B, Senser M. Falsely elevated international normalized ratio values in patients undergoing anticoagulation therapy: a descriptive evaluation. Chest 2007;131(3): Newman DH, Zhitomirsky I. The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med 2006;48(2): van den Besselaar AMHP, Hoekstra MMCL, Witteveen E, Didden JH, van der Meer FJM. Influence of blood collection systems on the prothrombin time and international sensitivity index determined with human and rabbit thromboplastin reagents. Am J Clin Pathol 2007;127(5): McGlasson DL. A comparison of INRs after local calibration of thromboplastin international sensitivity indexes. Clin Lab Sci 2002;15(2): McGlasson DL. Laboratory variables that may affect test results in prothrombin times (PT)/international sensitivity indexes. Clin Lab Sci 2003;34: McGlasson DL, Shaklee PN. A multi-instrument evaluation of a commercial chromogenic factor X assay to monitor oral anticoagulation therapy. Blood 2004;104(11): Shaklee PN, McGlasson DL. A multi-instrument evaluation of a chromogenic factor X assay for monitoring oral anticoagulation therapy. Clin Chem 2005;51(Suppl 1): Ortel TL, Moll S. Monitoring oral anticoagulant therapy in patients with lupus anticoagulants.[comment]. Br J Haematol 1998;101(2):

References 9. Robert A, Le Querrec A, Delahousse B, Caron C, Houbouyan L, Boutiere B, et al. Control of oral anticoagulation in patients with the antiphospholipid syndrome--influence of the lupus anticoagulant on International Normalized Ratio. Groupe Methodologie en Hemostase du Groupe d'Etudes sur l'Hemostases et la Thrombose. Thromb Haemostasis 1998;80(1): Rosborough TK, Shepherd MF. Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 2004; 24(7): Thom J, Ivey L, Gilmore G, Eikelboom JW. Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. Blood Coagul Fibrinolysis 2004;15(4): Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy 2005;25(2): Perry SL, Samsa GP, Ortel TL. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. Thromb Haemostasis 2005: 94(6): Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome.[see comment]. N Engl J Med 1995;332(15): Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome.[see comment]. N Engl J Med 2002;346(10): Sanfelippo MJ, Sennet J, McMahon EJ. Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant. WMJ 2000 Jun;99(3): Trask AS, Gosselin RC, Diaz JA, Dager WE. Warfarin initiation and monitoring with clotting factors II, VII, and X. Ann of Pharmacotherapy 2004 Feb;38: